Location of LMNA Variants and Clinical Outcomes in Cardiomyopathy

Heart, Artery and Coronary Diseases

Physical Activity and Cardiovascular Outcomes in Phenotype-Negative Cardiomyopathy Variant Carriers

JAMA Cardiol

Ajufo E, Kany S, Jurgens SJ, Churchill TW, Guseh JS, Aragam KG, Nauffal V, Pirruccello JP, Choi SH, Lakdawala NK, Ho CY, Ellinor PT, Khurshid S

doi: 10.1001/jamacardio.2025.4466

Heart, Artery and Coronary Diseases

Characterizing High-Risk Enrollment Criteria and Impact on Clinical Outcomes in a Large Randomized Clinical Trial: Insights From the TWILIGHT Trial

Am Heart J

Steg PG, Nicolas J, Baber U, Sartori S, Zhang Z, Feng Y, Angiolillo DJ, Briguori C, Cohen DJ, Collier T, Dangas G, Dudek D, Escaned J, Gibson CM, Han YL, Huber K, Kastrati A, Kaul U, Marx SO, Kornowski R, Kunadian V, Vogel B, Oliva A, Mehta SR, Moliterno D, Sardella G, Krucoff M, Shlofmitz RA, Sharma S, Pocock S, Mehran R

doi: 10.1016/j.ahj.2025.01.016

Atrial Fibrillation

3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation: Results From the SWISS-APERO Randomized Clinical Trial

J Am Coll Cardiol

Galea R, De Marco F, Aminian A, Meneveau N, Chalkou K, Anselme F, Gräni C, Franzone A, Vranckx P, Fischer U, Valgimigli M, Räber L

doi: 10.1016/j.jacc.2025.03.535

Atrial Fibrillation

Cardiomyopathy-Associated Gene Variants in Atrial Fibrillation

JAMA Cardiol

Wijdeveld LFJM, Ajufo E, Challa SP, Rämö JT, Wang X, Kany S, Halford JL, Weng LC, Choi SH, Aragam KG, van Tintelen JP, Brundel BJJM, Jurgens SJ, Ellinor PT

doi: 10.1001/jamacardio.2025.0460

Heart Failure

Effects of dapagliflozin on blood volume status and vascular outcomes in clinically stabilized heart failure patients after an acute decompensated heart failure event (DAPA-VOLVO study): Protocol of a double-blind randomized controlled clinical trial

PLoS One

Bitos K, Laptseva N, Haider T, Rossi VA, Nägele MP, Barthelmes J, Ruschitzka F, Sudano I, Flammer AJ

doi: 10.1371/journal.pone.0325668

Heart, Artery and Coronary Diseases

Body Mass Index and 10-Year Clinical Outcomes After Percutaneous Coronary Intervention-Interaction with Age, Sex, Diabetic Status and Clinical Presentation

J Clin Med

Ndrepepa G, Kufner S, Cassese S, Joner M, Xhepa E, Sager HB, Schunkert H, Kastrati A

doi: 10.3390/jcm14051413

Further Publications

Prevalence and Clinical Implications of Sleep Apnea in Hypertrophic Cardiomyopathy

JAMA Cardiol

Karim S, Chahal A, Venkataraman S, Deshmukh AJ, Siontis KC, Mansukhani M, Konecny T, Khanji MY, Petersen SE, Gersh BJ, Geske JB, Somers VK

doi: 10.1001/jamacardio.2025.2877

Heart Failure

Early genetic screening and cardiac intervention in patients with cardiomyopathies in a multidisciplinary clinic

ESC Heart Fail

Sadasivan C, Gagnon LR, Hazra D, Wang K, Youngson E, Thomas J, Chan AYM, Paterson DI, McAlister FA, Dzwiniel T, Tymchak W, Christian S, Oudit GY

doi: 10.1002/ehf2.15202

ESC 2025

Cardiovascular Risk and Diseases

Related content

Physical Activity and Cardiovascular Outcomes in Phenotype-Negative Cardiomyopathy Variant Carriers

Characterizing High-Risk Enrollment Criteria and Impact on Clinical Outcomes in a Large Randomized Clinical Trial: Insights From the TWILIGHT Trial

3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation: Results From the SWISS-APERO Randomized Clinical Trial

Cardiomyopathy-Associated Gene Variants in Atrial Fibrillation

Effects of dapagliflozin on blood volume status and vascular outcomes in clinically stabilized heart failure patients after an acute decompensated heart failure event (DAPA-VOLVO study): Protocol of a double-blind randomized controlled clinical trial

Body Mass Index and 10-Year Clinical Outcomes After Percutaneous Coronary Intervention-Interaction with Age, Sex, Diabetic Status and Clinical Presentation

Prevalence and Clinical Implications of Sleep Apnea in Hypertrophic Cardiomyopathy

Early genetic screening and cardiac intervention in patients with cardiomyopathies in a multidisciplinary clinic

Mavacamten monotherapy demonstrates sustained clinical benefits in obstructive hypertrophic cardiomyopathy